Download PDF
Aktuelle Ernährungsmedizin 2019; 44(05): 322-330
DOI: 10.1055/a-0942-9167
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Psychopharmaka-induzierte unerwünschte Wirkungen in der Ernährungstherapie

Relevance of Psychotropic Drug Adverse Effects in Nutritional Therapy
Katharina Schlumm
Institut für Ernährungsmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck
,
Christian Sina
Institut für Ernährungsmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck
,
Torsten Schröder
Institut für Ernährungsmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck
,
Martin Smollich
Institut für Ernährungsmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck
› Author Affiliations
Further Information

Publication History

Publication Date:
23 October 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Metabolische Effekte von Psychopharmaka sind sehr häufig – dies gilt insbesondere für appetitsteigernde Wirkungen und die Zunahme von Körpergewicht. Besonders stark mit einer Gewichtszunahme assoziiert sind Antipsychotika (Neuroleptika) und einige Antidepressiva (Mirtazapin, Lithium, Trizyklika). Resultierende metabolische Veränderungen sind häufig klinisch relevant, da sie sich negativ auf die kardiovaskuläre Morbidität und Mortalität auswirken können. Insbesondere bei Patienten unter Therapie mit Antipsychotika sollten regelmäßig Kontrolluntersuchungen durchgeführt werden (Körpergewicht, Blutdruck, Blutzuckerspiegel, Cholesterin, Leber-/Nierenfunktion). Wirkstoffspezifische metabolische Nebenwirkungen können antizipiert und durch geeignete Ernährungs- und Verhaltensinterventionen abgemildert oder verhindert werden. Alternativ sollte ärztlicherseits auch ein Wirkstoffwechsel erwogen werden, falls die Nebenwirkungen die Lebensqualität des Patienten relevant beeinträchtigen. Bei Unwirksamkeit anderer Maßnahmen zur Gewichtskontrolle kann die Anwendung von Orlistat bzw. Metformin (off-label) versucht werden.

Abstract

Metabolic effects of psychotropic drugs are very common – which primarily is the case due to appetite-enhancing and body weight increasing effects. In particular, use of antipsychotics (neuroleptics) and some antidepressants (mirtazapine, lithium, tricyclics) is associated with weight gain. Resulting metabolic changes often are clinically relevant as they may negatively impact cardiovascular morbidity and mortality. Especially in patients receiving antipsychotics, regular checkup should be executed (body weight, blood pressure, blood glucose, cholesterol, hepatic/renal function). A specific metabolic monitoring should be implemented. Drug-specific metabolic side effects can be anticipated and mitigated or prevented by appropriate nutritional and behavioural interventions. Alternatively, the physician should also consider a change in drug, if the side effects impair the quality of life of the patient relevantly. If other measures remain ineffective for weight control, application of orlistat or metformin (off-label) may be tried.

Schlüsselwörter

Psychopharmaka - Antidepressiva - Antipsychotika - unerwünschte Arzneimittelwirkungen - Ernährungstherapie

Keywords

psychotropic drugs - antidepressants - antipsychotics - adverse drug reactions - nutritional therapy
 

  • Literatur

  • 1 Schwabe U, Paffrath D, Ludwig W-D. et al. Arzneiverordnungsreport 2018. 1.. Auflage. Berlin, Heidelberg: Springer-Verlag; 2018
    Google Scholar
  • 2 Benkert O, Hippius H. Kompendium der psychiatrischen Pharmakotherapie. 11.. Auflage. Berlin, Heidelberg: Springer-Verlag; 2017
    Google Scholar
  • 3 Nielsen S. Benzodiazepines. Curr Top Behav Neurosci 2017; 34: 141-159
    PubMedGoogle Scholar
  • 4 Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48: 209-225
    CrossrefPubMedGoogle Scholar
  • 5 Siafis S, Tzachanis D, Sarama M. et al. Antipsychotic Drugs: from receptor-binding profiles to metabolic side effects. Curr Neuropharmacol 2018; 16: 1210-1223
    CrossrefPubMedGoogle Scholar
  • 6 Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013; 42: 545-563
    CrossrefPubMedGoogle Scholar
  • 7 Crichton GE, Elias MF, Robbins MA. Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: the Maine-Syracuse Study. BMC Public Health 2016; 16: 502
    CrossrefPubMedGoogle Scholar
  • 8 Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease modifying effects and treatment implications. Int J Bipolar Disord 2016; 4: 13
    CrossrefPubMedGoogle Scholar
  • 9 Allison DB, Newcomer JW, Dunn AL. et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009; 36: 341-350
    CrossrefPubMedGoogle Scholar
  • 10 Butnoriene J, Bunevicius A, Norkus A. et al. Depression but not anxiety is associated with metabolic syndrome in primary care-based community sample. Psychoneuroendocrinology 2014; 40: 269-276
    CrossrefPubMedGoogle Scholar
  • 11 Zanoveli JM, Morais H, Dias IC. et al. Depression associated with Diabetes: From pathophysiology to treatment. Curr Diabetes Rev 2016; 12: 165-178
    CrossrefPubMedGoogle Scholar
  • 12 Atlantis E, Browning C, Sims J. et al. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010; 25: 688-696
    PubMedGoogle Scholar
  • 13 Luppino FS, de Wit LM, Bouvy PF. et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-229
    CrossrefPubMedGoogle Scholar
  • 14 Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in nevertreated chronic schizophrenia. Schizophr Res 2010; 121: 199-202
    CrossrefPubMedGoogle Scholar
  • 15 Sengupta S, Parrilla-Escobar MA, Klink R. et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr Res 2008; 102: 329-336
    CrossrefPubMedGoogle Scholar
  • 16 Dent R, Blackmore A, Peterson J. et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One 2012; 7: 1-13
    CrossrefPubMedGoogle Scholar
  • 17 Wharton S, Raiber L, Serodio KJ. et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes Target Ther 2018; 11: 427-438
    PubMedGoogle Scholar
  • 18 Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci 2016; 1391: 20-34
    PubMedGoogle Scholar
  • 19 Champaneri S, Wand GS, Malhotra SS. et al. Biological basis of depression in adults with diabetes. Curr Diab Rep 2010; 10: 396-405
    CrossrefPubMedGoogle Scholar
  • 20 Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035-1059
    CrossrefPubMedGoogle Scholar
  • 21 Dayabandara M, Hanwella R, Ratnatunga S. et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017; 13: 2231-2241
    CrossrefPubMedGoogle Scholar
  • 22 Hosojima H, Togo T, Odawara T. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006; 20: 75-79
    CrossrefPubMedGoogle Scholar
  • 23 Goncalves P, Araujo JR, Martel F. Antipsychotic-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 2015; 25: 1-16
    CrossrefPubMedGoogle Scholar
  • 24 Stefanidis A, Verty AN, Allen AM. et al. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 2009; 17: 16-24
    CrossrefPubMedGoogle Scholar
  • 25 Blumenthal SR, Castro VM, Clements CC. et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry 2014; 71: 889
    CrossrefPubMedGoogle Scholar
  • 26 Kroeze WK, Hufeisen SJ, Popadak BA. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-526
    CrossrefPubMedGoogle Scholar
  • 27 Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272
    CrossrefPubMedGoogle Scholar
  • 28 Lee SH, Paz-Filho G, Mastronardi C. et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic?. Translational Psychiatry 2016; 6: e759
    CrossrefPubMedGoogle Scholar
  • 29 Stahl SM, Pradko JF, Haight BR. et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159-166
    CrossrefPubMedGoogle Scholar
  • 30 Naik BS, Shetty N, Maben EV. Drug-induced taste disorders. Eur J Intern Med 2010; 21: 240-243
    CrossrefPubMedGoogle Scholar
  • 31 Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Saf 2008; 31: 199-215
    CrossrefPubMedGoogle Scholar
  • 32 Hong JH, Omur-Ozbek P, Stanek BT. et al. Taste and odor abnormalities in cancer patients. J Supp Oncol 2009; 7: 58-65
    PubMedGoogle Scholar
  • 33 Abosi O, Lopes S, Schmitz S. et al. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig 2018; 36 DOI: 10.1515/hmbci-2017-0065.
    CrossrefPubMedGoogle Scholar
  • 34 Gahr M, Connemann BJ, Cabanis M. et al. Metabolische Nebenwirkungen von Psychopharmaka. Eine Analyse der Daten aus Fachinformationen. Nervenheilkunde 2016; 35: 559-569
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Zeiss R, Connemann BJ, Gahr M. Psychopharmakotherapie und metabolische Nebenwirkungen. Nervenheilkunde 2017; 36: 703-713
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Vuk A, Kuzman MR, Baretic M. et al. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Psychiatr Danub 2017; 29: 121-135
    PubMedGoogle Scholar
  • 37 Olfson M, Marcus SC, Corey-Lisle P. et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163: 1821-1825
    CrossrefPubMedGoogle Scholar
  • 38 McIntyre RS, Soczynska JK, Konarski JZ. et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5: 157-168
    CrossrefPubMedGoogle Scholar
  • 39 Derijks HJ, Meyboom RHB, Heerdink ER. et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008; 64: 531-538
    CrossrefPubMedGoogle Scholar
  • 40 Canfrán-Duque A, Casado ME, Pastor Ó. et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 2013; 54: 310-324
    CrossrefPubMedGoogle Scholar
  • 41 Raeder MB, Fernø J, Glambek M. et al. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006; 395: 185-190
    CrossrefPubMedGoogle Scholar
  • 42 Nagata M, Nakajima M, Ishiwata Y. et al. Mechanism underlying induction of hyperglycemia in rats by single administration of olanzapine. Biol Pharm Bull 2016; 39: 754-761
    CrossrefPubMedGoogle Scholar
  • 43 Ikegami M, Ikeda H, Ohashi T. et al. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′-monophosphate-activated protein kinase. Diabetes Obes Metab 2013; 15: 1128-1135
    CrossrefPubMedGoogle Scholar
  • 44 Burghardt KJ, Goodrich JM, Dolinoy DC. et al. DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics 2015; 7: 343-352
    CrossrefPubMedGoogle Scholar
  • 45 Maier L, Pruteanu M, Kuhn M. et al. Extensive impact of non-antibiotic drugs on human gut microbiota. Nature 2018; 555: 623-628
    PubMedGoogle Scholar
  • 46 Sarkar A, Harty S, Lehto SM. et al. The microbiome in psychology and cognitive neuroscience. Trends Cogn Sci 2018; 22: 611-636
    CrossrefPubMedGoogle Scholar
  • 47 Himmerich H, Schuld A, Haack M. et al. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 2004; 38: 485-489
    CrossrefPubMedGoogle Scholar
  • 48 Kloiber S, Domschke K, Ising M. et al. Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry 2015; 76: e802-808
    CrossrefPubMedGoogle Scholar
  • 49 Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M. et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009; 43: 620-626
    CrossrefPubMedGoogle Scholar
  • 50 Strassnig M, Miewald J, Keshavan M. et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007; 93: 90-98
    CrossrefPubMedGoogle Scholar
  • 51 Bak M, Fransen A, Janssen J. et al. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS ONE 2014; 9: e94112
    CrossrefPubMedGoogle Scholar
  • 52 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. Behandlungsleitlinie Schizophrenie. Heidelberg: Steinkopff-Verlag; 2006
    Google Scholar
  • 53 Schefft C, Kilarski LL, Bschor T. et al. Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2017; 27: 1090-1109
    CrossrefPubMedGoogle Scholar
  • 54 Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: A systematic review. J Clin Pharm Ther 2017; 42: 394-403
    CrossrefPubMedGoogle Scholar
  • 55 Sarris J, Murphy J, Mischoulon D. et al. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry 2016; 173: 575-587
    CrossrefPubMedGoogle Scholar
  • 56 Fiedorowicz JG, Miller DD, Bishop JR. et al. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev 2012; 8: 25-36
    CrossrefPubMedGoogle Scholar
  • 57 Tchoukhine E, Takala P, Hakko H. et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011; 72: 326-330
    CrossrefPubMedGoogle Scholar
  • 58 Wang M, Tong J, Zhu G. et al. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr Res 2012; 138: 54-57
    CrossrefPubMedGoogle Scholar
  • 59 Jarskog LF, Hamer RM, Catellier DJ. et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013; 170: 1032-1040
    CrossrefPubMedGoogle Scholar
  • 60 Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am 2009; 32: 775-794
    CrossrefPubMedGoogle Scholar
  • 61 Daumit GL, Goldberg RW, Anthony C. et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 2005; 193: 641-646
    CrossrefPubMedGoogle Scholar
  • 62 Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues Ment Health Nurs 2011; 32: 589-597
    CrossrefPubMedGoogle Scholar
  • 63 Green CA, Yarborough BJ, Leo MC. et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015; a 172: 71-81
    CrossrefPubMedGoogle Scholar
  • 64 Green CA, Yarborough BJ, Leo MC. et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. Obesity (Silver Spring) 2015; b 23: 1995-2001
    CrossrefPubMedGoogle Scholar
  • 65 Daumit GL, Dickerson FB, Wang NY. et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368: 1594-1602
    CrossrefPubMedGoogle Scholar
  • 66 Fink A, Cieslak S, Rosenbach F. Nichtpharmakologische Interventionen zur Prävention von Gewichtszunahme bei schizophrenen Patienten unter antispychotischer Medikation. Psychiat Prax 2015; 42: 359-369
    Article in Thieme ConnectPubMedGoogle Scholar